SG Americas Securities
FOLD

SG Americas Securities’s Amicus Therapeutics FOLD Stock Holding History

SG Americas Securities’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,000
Closed -$65K – 3347
2017
Q3 		$65K Buy
+50,000
New +$661K ﹤0.01% 3282

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

SG Americas Securities's FOLD Position: Q1 2026 in Review

SG Americas Securities increased its Amicus Therapeutics (FOLD) stake by 269% in Q1 2026, buying an estimated $4.11M and bringing the position to 392,835 shares worth $5.68M. The position accounts for 0.01% of the portfolio, ranked #999.

SG Americas Securities first reported a position in FOLD in Q2 2013 and has held it in 36 quarters since. The position peaked at $5.77M in Q2 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • SG Americas Securities held 392,835 shares of Amicus Therapeutics worth $5.68M as of Q1 2026.
  • SG Americas Securities bought 286,477 Amicus Therapeutics shares in Q1 2026, an estimated $4.11M.
  • Amicus Therapeutics made up 0.01% of SG Americas Securities's portfolio in Q1 2026, its #999 holding.
  • SG Americas Securities first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 36 quarters since.
  • SG Americas Securities's Amicus Therapeutics position peaked at $5.77M in Q2 2020.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.